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Variation in skin color is the major host risk factor for melanoma and other forms of skin cancer. Individuals with
red hair show an increased ratio of phaeomelanin to eumelanin in both hair and skin. This ratio is regulated by the
melanocortin (MC) 1 receptor. There are several common point mutations in the human MC1 receptor that are
overrepresented in North European red-heads, and in individuals with pale skin. In order to determine the func-
tional significance of these mutations, we expressed the Asp84Glu, Val92Met, Arg163Gln, and Asp294His variants
of the human MC1 receptors in eukaryotic cells and determined their ability to bind a-melanocyte stimulating
hormone (MSH) peptides and increase intracellular cAMP. The mutants Asp84Glu and Asp294His showed a much
lower response to a-MSH in cAMP and a slightly impaired ability to bind a-MSH, and the Val92Met mutant bound a-
MSH with 100-fold lower afﬁnity as compared with the wild-type. The Arg163Gln variant, widely found in some Asian
populations, reached normal level of cAMP response but had just slightly lower potency for a-MSH in binding and
second messenger studies. The results provide important pharmacological characterization of common MC1
receptor variants in various world populations.
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The melanocortin (MC) system is ancient and arose very
early in vertebrate evolution. The melanocortin ligands,
which originate from the precursor peptide proopiomela-
nocortin (POMC), are remarkably conserved throughout
vertebrates. Moreover, our recent studies (Ringholm et al,
2002) show that pharmacological and functional properties
as well as gene structure and syntenic relationships of the
melanocortin receptors have been highly conserved over a
period of more than 400 million years. The MC receptors are
G-protein coupled receptors (GPCR) with five subtypes in
mammals and chicken. The teleost species zebrafish has
additional copy of the MC5 receptor and another teleost
species fugu is lacking the MC3 receptor (Klovins et al,
2004). Despite high structural and genetic conservation of
the MC receptors, the physiological role of each subtype is
very diverse. The MC1 receptor has a defined role in pig-
mentation and may also play a role in mediating some of the
anti-inflammatory actions of melanocyte stimulating hor-
mone (MSH). The MC2 receptor subtype mediates the
function of adrenocorticotropic hormone (ACTH). The MC4
receptor has a fundamental role in control of feeding and
body weight (Schio¨th, 2001) and the MC3 receptor is also
involved in regulation of the energy balance although in dif-
ferent manner. The MC5 receptor has a role in exocrine
gland function.
The variation in hair and skin color in man principally
depends of the amount of epidermal melanin. There are two
forms of epidermal melanin, eumelanin (which has black–
brown color) and pheomelanin (which is red–yellow). The
relative production of these two types of melanin, at least in
mouse, is controlled by the extension (E) locus and agouti
(A) locus that regulate the relative amount of these two
forms of melanin (Rees, 2003). The E locus encodes the
MC1 receptor and the A locus encodes the agouti peptide
which is an antagonist at the MC1 receptor. The significance
of these agouti and MC1 receptor in pigmentation was in-
itially found in mice (Robbins et al, 1993) but has now been
shown to have similar role in other mammals like cattle, fox,
horses, pigs, sheep, and dogs (Rees, 2003). The role of
agouti in man is, however, at least in terms of pigmentation,
still not fully understood. A large number of genes are
known to effect coat color in mice, but in man, with the
exception of rare Mendelian disorders, such as albinism,
only one gene, the MC1, is known to influence skin and hair
color. The MC1 receptor is expressed on the surface of
Abbreviations: ACTH, adrenocorticotropic hormone; cAMP, cyclic
adenosine-mono-phosphate; COS-1, CV-1 Origin SV40; DMEM,
Dulbecco’s modified Eagle’s medium; EL, extracellular loops;
GPCR, G-protein coupled receptors; HEK, human embryonic kid-
ney; IL, intracellular loops; Kd, dissociation constant from satura-
tion studies; Ki, dissociation constant from competition studies;
MC, melanocortin; MSH, melanocyte stimulating hormone; NDP-
MSH, [Nle4, D-Phe7] a-MSH; POMC, proopiomelanocortin; TM,
transmembrane
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
917
melanoma cells and melanocytes in the skin (Schio¨th,
2001). Stimulation of the MC1 receptor by a-MSH causes
increased eumelanin synthesis, whereas absence of a-
MSH, or inhibition of a-MSH by the antagonist agouti pro-
tein, leads to pheomelanin synthesis. It has been shown that
loss-of-function mutation in MC1 receptor results in yellow
hair in mouse, and red hair in man and some other animals,
as a result of overproduction of pheomelanin. Gain-of-func-
tion mutations, however, lead to excess eumelanin syn-
thesis and a dark coat (Rees, 2003). MC1 receptor gain-
of-function mutations have interestingly not been described
in man.
The human MC 1 receptor shows very high degree of
polymorphism (Schaffer and Bolognia, 2001). To date, more
than 40 different alleles of the human MC1 receptor have
been identified (Rees, 2000; Bastiaens et al, 2001; Peng
et al, 2001; John and Ramsay, 2002). Particular variants of
the MC1 receptor gene, such as the Arg151Cys, Arg160Trp,
and Asp294His, have been associated with red hair and fair
skin and the inability to tan in humans, and the frequency of
these alleles is also higher, as expected in persons with
melanoma or other common forms of skin cancer (Healy
et al, 2000, 2001). There are numerous studies that asso-
ciate genetic variants of the MC1 receptors with physiolog-
ical characteristics but detailed pharmacological studies on
the majority of variants have not been preformed. Apart
from the need to ensure that the variants are causally im-
plicated in determining phenotype, rather than just been in
linkage disequilibrium with other changes, better under-
standing of the role of the specific residues within MC1 re-
ceptor may provide better understanding of the structural
requirements that influence the ligand recognition and the
complex mechanisms of signal transduction of GPCRs.
In this study, we have expressed some of the common
naturally occurring variants of human MC1 receptor (Asp84-
Glu, Val92Met, and Arg163Gln), and for comparison with
previous studies, the Asp294His in eukaryotic cells, and
characterized them with regard to binding properties and
ability to activate adenylyl cyclase. Our choice of variants is
in part determined by their frequency (Val92Met, Arg163Gln)
and by their putative causal role determining skin pheno-
type (Arg163Gln).
Results
In order to pharmacologically characterize the Asp84Glu,
Val92Met, and Arg163Gln and wild-type human MC1 re-
ceptors, their genes were transferred into expression vec-
tors, sequenced to confirm the presence of the expected
single base pair change, tranfected into eucaryotic cells and
tested in radioligand binding and second messenger as-
says. We had previously performed similar studies on the
Asp294His mutant (Schio¨th et al, 1999). Figure 1 shows the
results of the competition binding of a-MSH for the different
receptors. Table I shows the Kd (dissociation constant from
saturation studies) and Ki (dissociation constant from com-
petition studies) values obtained from saturation and com-
petition experiments, respectively. The results show that the
ligands bind to a single saturable site for all the receptors.
Saturation experiments with [125I]NDP-MSH ([Nle4, D-Phe7]
a-MSH) did not show any difference in binding among
Asp84Glu, Val92Met, Arg163Gln, and Asp294His mutants
compared with wild-type human MC1 receptor. Our Kd val-
ue for the Asp294His mutant was also indistinguishable
from the Kd in earlier study (Schio¨th et al, 1999). Moreover,
the Ki values for NDP-MSH for the mutants were also in the
same range as for the wild-type hMC1 receptor. All of the
mutants had higher affinity for NDP-MSH than for a-MSH,
which is in line with earlier studies on the human MC1 re-
ceptor (Schio¨th et al, 1995; Schio¨th et al, 1999). The Asp84-
Glu, Arg163Gln, and Asp294His mutants show a slightly
lower affinity (approximately 10–20-fold) to the a-MSH as
compared with the wild-type human MC1 receptor. The re-
sults on the Asp294His mutant were in good agreement
with our previous binding experiments on this mutant show-
ing about 7-fold lower affinity of this mutant as compared
with the wild-type whereas the binding of NDP-MSH was
similar. The binding method has been very reliable and re-
producible for a long period in the lab independent of the
cell type used. We have compared the two cell types, COS
(CV Origin SV 40) and HEK293-EBNA, several times on our
lab, and found that they give the same results in binding
studies (Ringholm et al, 2002; Lagerstro¨m et al, 2003). The
Val92Met mutant had, however, clearly lower affinity to a-
MSH (about 100-fold) comparing to the wild-type receptor.
This mutant was previously shown to respond with 5-fold
lower affinity for a-MSH as compared with the wild-type (Xu
et al, 1996).
The ability of the mutants to elevate production of cAMP
after stimulation with a-MSH was measured and compared
with wild-type human MC1 receptor. The mutants and wild
human MC1 receptor genes were transiently expressed in
Figure1
Radioligand binding. Competition studies showing the affinity of a-
MSH to the wild-type (’) MC1 receptor and the Asp84Glu (  ),
Val92Met (m) and Arg163Gln (E) MC1 receptor mutants. Competition
curves are obtained using COS-1 cells transfected with the various
MC1 receptors using a fixed concentration of nM [125I][Nle4, D-Phe7]a-
MSH and varying concentrations of a-MSH. Lines represent the com-
puter-modelled best fit of the data assuming that ligands bound to one-
site.
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HEK293-EBNA cells. The EBNA cells are more appropriate
for the second messengers studies as compared with the
COS cells that we have used earlier (Schio¨th et al, 1999).
The response of the transfected EBNA cells is much higher
as a ratio of the basal levels as compared with the COS
cells. Moreover, the method that we use for the cAMP
measurement has been changed and has become more
sensitive and reproducible. Our previous method did not
provide sigmoid curves and it was not as informative to-
wards the maximum level and EC50 (effective concentration)
values as the current one. Non-transfected HEK293-EBNA
cells did not respond to a-MSH. The presence of MC re-
ceptors on the HEK293-EBNA cells during the cAMP assay
was confirmed by radioligand binding that also indicated
similar binding values as compared with the results that we
reported in COS cells (data not shown). Moreover, the Bmax
values calculated in saturation studies in all five receptors
expressed in EBNA cells were roughly in the same range
(data not shown). The cells transfected with different re-
ceptor variants were diluted equally during the experiments
in order to assure approximately equal number of receptors
when we performed both the binding and cAMP assays.
The Arg163Gln mutant showed similar ability to respond
to a-MSH as the wild-type MC1 receptor, whereas Asp84-
Glu and Val92Met and Asp294His mutant MC1 receptor
variants showed clearly impaired ability to respond to a-
MSH. The maximum response of the Asp84Glu and
Asp294His mutants indicates that they were virtually non-
responsive as compared with the wild-type. The result of
Asp294His was in general agreement with the earlier stud-
ies (Schio¨th et al, 1999). These previous studies had
showed that the receptor’s response to a-MSH was not
distinguishable from the non-transfected cells in the second
messengers experiments using COS cells. Our new results,
however, show clearly (see the small illustration in Fig 2) that
this mutant responds to a-MSH, although only to the extent
of 6% as compared with the wild-type. Interestingly, we
could calculate an EC50 value that was very similar to that of
the wild-type (see Table I). The mutant Asp84Glu was also
shown to have a small response and that the EC50 value
was also similar to that of the wild-type.
Our results indicate that the Val92Met mutant has lower
EC50 value and lower maximum response as compared
with the wild-type. The maximum response of this mutant is,
however, much higher as compared with the Asp84Glu and
Asp294His mutants. Previous studies showed that this mu-
tant had indistinguishable response to a-MSH as compared
with the wild-type (Koppula et al, 1997) assayed using a
cAMP-dependent b-galactosidase reporter.
Discussion
In our previous study published in 1999, we characterized
five naturally occurring common variants of human MC1, all
of them represented in North European population (Schio¨th
et al, 1999). All these five mutants, Val60Leu, Arg142His,
Arg151Cys, Arg160Trp, and Asp294His showed a clearly
impaired ability to stimulate cAMP production in response to
a-MSH stimulation when compared with the wild-type re-
ceptor. The binding to NDP-MSH was not impaired, but the
mutants had lower affinity for the natural ligand a-MSH. The
response of the mutants to a-MSH was indistinguishable
from that of non-transfected cells in the second messenger
Table I. Ki, Kd, and EC50 values (mean  SEM) obtained from competition, saturation and cAMP assay curves, respectively,
for melanocortin (MC) peptides analogues on wt hMC1 receptor and Asp84Glu, Val92Met, Arg163Gln, and Asp294His hMC1
receptor mutants
Ligand/receptor [125I] NDP-MSH Kd (nmol per L) NDP-MSH Ki (nmol per L) a-MSH (Ki) (nmol per L) a-MSH EC50 (nmol per L)
MC1R wt 0.210  0.041 0.332  0.222 0.220  0.035 1.809  0.646
Asp84Glu-MC1R 0.910  0.124 0.594  0.170 2.83  0.65 3.932  1.66
Val92Met-MC1R 0.511  0.090 0.310  0.103 21.4  6.7 9.202  7.48
Arg163Gln-MC1R 0.534  0.141 0.208  0.067 4.20  0.71 4.382  1.26
Asp294His-MC1R 0.638  0.125 0.392  0.339a 5.81  2.21a 3.825  1.11
aData taken from Schio¨th et al (1999).
Ki, dissociation constant from competition studies; Kd, dissociation constant from competition studies; MSH, melanocyte stimulating hormone; NDP-
MSH, [Nle4, D-Phe7] a-MSH.
Figure2
Second messenger study. Generation of cAMP in respons to a-MSH
in HEK293-EBNA cells transfected with wild-type (’) MC1 receptor
and the different MC1 receptor mutants: Asp84Glu (  ), Val92Met (m),
Arg163Gln (E) and Asp294His (&). Each point represents the aver-
age  SEM. Untransfected HEK293-EBNA (  ) cells showed no AC-
activity in response to a-MSH. The small figure, in the right upper
corner, is an enlargement of the three curves with lowest cAMP re-
sponse (HEK293-EBNA (  ), Asp84Glu (  ) and Asp294His (&)) from
the main figure. The cAMP assay was performed in duplicates and
repeated three times for each receptor.
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studies, with the exception of the Val60Leu, which showed a
slightly higher cAMP response, compared with the other
mutants. Since these studies, we have improved our second
messengers system. In this study, we wanted to carefully
investigate the response of four MC1 receptors mutants
(Asp84Glu, Val92Met, Arg163Gln, and Asp294His) in order
to better understand the functional status of these receptors.
A number of allelic association studies have previously been
published between these alleles and skin and hair pheno-
types. The Asp294His mutant has also been tested in our
previous study (Schio¨th et al, 1999).
The Asp84Glu mutant is a rare variant of the MC1 re-
ceptor that has been associated with fair skin/red skin in-
dividuals (Valverde et al, 1995). In a study from 1996
(Valverde et al, 1996), this mutant was also linked with me-
lanoma skin cancer but later studies failed to confirm these
results (Healy et al, 1999; Helsing and Hoyheim, 2001).
There are no previous results on the functionality of this
mutant except that Koppula et al, 1997 wrote that in ‘‘pre-
liminary experiments’’ that Asp84Glu was functional with
the ability to stimulate production of cAMP in the range
comparable with the wild-type receptor. Our results indicate
that this mutant has 10-fold lower affinity as compared with
the wild-type. Moreover, this mutant showed low ability to
respond to a-MSH as the maximum response was only
15% of the wild-type receptors. We can thus conclude that
this mutant supports our previous suggestion that ‘‘loss of
function’’ mutants are common within the red-haired pop-
ulation. Interestingly, this mutant has still an inherent ability
to mediate a signal in a dose response manner at similar
concentration as the wild-type receptor (see Fig 2).
The Val92Met mutant has been found to be frequent in
population, present in individuals with light and deep red
hair as well as in individuals with skin type I (always burn,
never tan) and type II (always burn, then tan) (Xu et al, 1996).
The results from our study indicates that the Val92Met var-
iant had approximately 100-fold lower affinity to a-MSH as
compared with the wild-type receptor. Our results thus
confirm the previous result (Xu et al, 1996) that suggested
that the binding was impaired, showing about 5-fold lower
affinity to a-MSH. The results indicate, however, a greater
difference in the affinity of the mutant as compared with the
wild-type. Our new results are in some contrast to results
obtained in Koppula et al, 1997 using a cAMP-dependent
b-galactosidase reporter assay when this mutant was found
to respond in manner similar to the wild-type. The findings
indicate that this mutant has both impaired ability to re-
spond to low concentrations of the ligand, which is in line
with the binding results, and impaired ability to reach the
same maximum response as the wild-type receptor. These
new results strengthen thus the conclusions about the con-
nection between the functionality of this mutant and the
red-haired phenotype.
The Arg163Gln mutant has been found to be most fre-
quent in East and Southeast Asians but also present in In-
dians, in much lower frequency, however (Rana et al, 1999).
There is, however, no clear evidence that directly couple this
mutant to any specific phenotype. We found that this mu-
tant had about 20-fold lower affinity for a-MSH as compared
with the wild–type, whereas in the second messenger study
the response reached a maximum response similar to the
wild-type, which is in contrast to the other mutants we have
tested earlier. The mutant responded at only slightly lower
concentration as compared with the wild-type. This may
reflect the lower binding affinity indicating that the signalling
ability itself is not affected. It is thus likely that this mutation
alone does not have important role in supporting the red-
haired phenotype.
The Asp294His variant of the human MC1 receptor has
been found to be highly polymorphic in European popula-
tion (Harding et al, 2000) and found to cause a loss-of-
function mutation due to its inability to produce intracellular
cAMP via activation of adenylate cyclase (Schio¨th et al,
1999). We used this mutant mainly as control for our new
second messengers assay and we confirmed that it is vir-
tually non-responsive to a-MSH. It is, however, interesting
that the data show that three of these different mutants,
including the Asp294His, do still have residual response to
a-MSH at concentrations that are not far from that of the
wild-type. The data may suggest that many polymorphic
variants of the MC1 receptors have a residual ability to re-
spond to MSH ligands, which in turn may complicate the
linkage studies considerably. It seems that the simple con-
cept that the receptors are either turned on or off is not
applicable to these receptors. Interpretation of the func-
tional ability of these mutants is also hampered by the fact
that different laboratories have different experimental set-
ups. We also want to point out the importance of how the
primary data are calculated. Pharmacological response
data are frequently normalized, which means that the basal
and the maximum response levels are fixed whereas the
EC50 value is used to draw conclusions. This has the ad-
vantage that experimental data from mutants with different
expression levels can be compared. Indeed it is our expe-
rience that mutant receptors, in particular those that are
‘‘artificially’’ generated through, e.g., site-directed muta-
genesis are often expressed in at lower levels as compared
with the wild-type receptors. It appears, however, evident
from this study that the evaluation of the maximum re-
sponse is equally as important as the determination of the
EC50 value, when characterizing different variants of the MC
receptors. The number of expressed receptors can be test-
ed through different tags (His, Flag, etc.) and antibodies, but
these measurements are usually not as accurate to meas-
ure the amount of functional proteins as the radioligand
binding assay. There is thus large advantage if binding and
second messenger studies can be performed on the same
cell cultures.
There is increasing information about structural compo-
nent that participate in how the MC receptors may recog-
nize their ligands and transduce their signals. There are
several models of the MC1 and also the MC4 receptor
(Haskell-Luevano et al, 1996; Prusis et al, 1997; Lagerstro¨m
et al, 2003). The mutation Arg163Gln can be found in the
middle of transmembrane (TM)4 that has been suggested to
be somewhat distant from the main binding pocket of MSH
peptides. Moreover, it does not seem to have a key position
for the signalling process if it is the TM3 that rotates during
the signal transduction process as recently suggested
(Lagerstro¨m et al, 2003). It is thus likely that the slight effect
on binding is probably related to unspecific conformation
change of the receptor. Mutations Asp84Glu and Val92Met
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are found in TM2 where most of the naturally occurring
mutations are found. The Val92 is found in the vicinity of the
Glu90 which when mutated to Lys gives rise to constitutive
activation within mice and chicken (Ling et al, 2003). Such
activation mutation has interestingly not been found in hu-
mans. Asp84 is found deeper down in the TM region and is
highly conserved through all MC receptor subtypes through
out the evolution. Considering the models of activation of
the MC receptor this residue could be involved both in the
binding and the activation process itself and this is reflected
in our pharmacological data. The Asp294 is close to the
intracellular part of TM7 that is also considered to be im-
portant for the MSH binding and likely to be important for
the activation that is in line with the pharmacological data. It
is important in this context that the mutations Asp84Glu and
Val92Met do not cause major changes in amino acid char-
acter, whereas the Arg163Gln and in Asp294His involves
more drastic changes. Taken together, the results from this
study confirm many of the recent proposals of the position
of the main sites of binding and activation of the MSH
peptides.
As we mention above, there are several studies reporting
on the high polymorphism in the human MC1 receptor. It is
also common that the red-headed persons have two allelic
variants of MC1 receptors (Rees, 2000). Some variants are
more frequent in individuals with sun-sensitive skin type I or
II, than in persons with higher basal pigmentation and tan-
ning response (Jimenez-Cervantes et al, 2001). The pattern
of diversity in MC1 receptor is lower in African populations
as well as in African Americans and in Asians from Papua
New Guinea and India, than in those from Northern Europe
(Harding et al, 2000). The Arg163Gln variant is not found in
the Africans studied so far, almost absent in Europeans, at
low frequency (7%) in Indians, but is exceptionally highly
frequent (70%) in East and Southeast Asians (Rana et al,
1999). There is no statistical evidence that MC1 receptor
diversity among Europeans and Asians has been enhanced
by selection, whereas in Africans, on the other hand, the
MC1 receptor is under strong functional constraint, where
the eumelanin production rather than pheomelanin, appears
to be an evolutionary benefit (Harding et al, 2000). In study
done by Rana et al (1999), the conclusions are slightly dif-
ferent. The nucleotide diversity at the MC1 locus is shown
to be several times higher than the average nucleotide di-
versity in human population, which would indicate that MC1
has evolved more rapidly.
In order to provide an overview of the known connection
between the pharmacology and the phenotypes, we creat-
ed a two-dimensional model of the MC1 receptor (Fig 3)
where the polymorphic positions are marked. This topology
is differing from those published previously (Schaffer and
Bolognia, 2001; Sanchez Mas et al, 2002) as it is drawn
using the relatively new crystal structure of bovine rhodop-
sin (Palczewski et al, 2000) that provides improved sug-
gestions about the boundaries between the loop and
helices. Among all variants of MC1 receptor, there are es-
pecially three that are extremely frequent, Arg151Cys,
Arg160Trp, and Asp294His. These are together found in
22% of the MC1 receptor genes in the Northern European
population and can be accounted for 60% of all cases
of red hair (Healy et al, 2001). Val60Leu, Arg142His,
Arg151Cys, Arg160Trp, and Asp294His are together present
in 30% of the North European population (Schio¨th et al,
1999). Arg151Cys, Arg160Trp, and Asp294His mutations
almost always result in red hair when homozygous, whereas
Asp84Glu, Arg142His, and Ile155Thr variants, which are
rare in population, act as recessive red hair alleles in com-
bination with the three more common variants of the MC1
receptor (Flanagan et al, 2000). To date, all studies informing
about functional properties of different mutants show that
mutations in TM1–TM3, TM6, and TM7 affect the ability to
respond to the natural ligands of the mutant comparing to
wild-type. Interestingly, there is no study reporting mutation
in TM5 that is linked to a phenotype. In general there is a
fairly good agreement between the structural models and
pharmacological studies on these naturally occurring mu-
tants. There are still several mutants that remain to be
characterized in order to get better view of how the specific
mutations that affect the human MC1 receptor.
In summary, we have characterized mutants of the hu-
man MC1 receptors. The results have clarified the func-
tionality of these mutant receptors and also given insight
into pharmacological characteristics of MC receptors var-
iants that are important for interpretation of results from the
second messenger studies. Moreover, the new data have
added to our knowledge regarding which structural ele-
ments within MC receptors are important for the pharma-
cology.
Materials and Methods
Chemicals NDP-MSH was radio-iodinated by the chloramine T
method and purified by HPLC (high-performance liquid chroma-
tography). NDP-MSH and a-MSH were purchased from Neosys-
tem, Strasbourg, France.
Receptors clones and expression The wild-type MC1 receptor
and the variant MC1 receptor genes Asp84Glu, Val92Met,
Arg163Gln, and Asp294His were amplified by PCR and cloned in-
to the expression vector pCR3.1 (Invitrogen, Carlsbad, California).
All constructs were re-sequenced after subcloning. For the binding
studies, COS-1 (CV-1 Origin, SV40) cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal calf serum.
Eighty percent confluent cultures were transfected with the DNA
mixed with liposomes in serum-free medium (for details see
Schio¨th et al, 1995). After transfection, the serum-free medium was
replaced by serum-containing medium and the cells were culti-
vated for about 48 h. For the cAMP studies, HEK 293-EBNA cells
were transfected with the pCEP4 vector constructs containing all
the variants of receptor genes using FuGENE Transfection Reagent
(Boehringer Mannheim, Roche, Stockholm, Sweden).
Binding studies The transfected cells were harvested by scrap-
ing, centrifuged, washed with binding buffer (Schio¨th et al, 1995)
and distributed into 96-well non-culture-coated plates, which were
centrifuged and the binding buffer removed. The cells were then
immediately incubated in the well plates for 2 h at 371C with 0.05
mL binding buffer in each well containing a constant concentration
of [125I]NDP-MSH and appropriate concentrations of competing
unlabelled ligand. After incubation, the cells were washed with
0.2 mL of ice-cold binding buffer and detached from the plates with
0.2 mL of 0.1 N NaOH. Radioactivity was counted (Wallac, Wizard
automatic gamma counter, Wallac, Turku, Finland) and data were
analyzed with appropriate software (Wan System AB, Umea˚, Swe-
den). The Kd values for [
125I]NDP-MSH for the MC receptors were
taken from previous studies (Schio¨th et al, 1995, 1996). The binding
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assays were performed in duplicate wells and repeated three
times. Untransfected COS-1 cells did not show any specific bind-
ing for [125I]NDP-MSH.
cAMP assay The wild-type MC1 receptor and the variant MC1
receptor genes Asp84Glu, Val92Met, Arg163Gln, and Asp294His
were amplified by PCR, purified and cloned into a modified pCEP4
expression vector as described earlier (Ringholm et al, 2003). The
new constructs were sequenced and found to be identical to the
original clones. HEK 293-EBNA cells were then transiently
transfected with the pCEP4 vector constructs using FuGENE
Transfection Reagent (Boehringer Mannheim, Roche) and diluted in
OptiMEM medium (Invitrogen Corporation) according to the man-
ufacturer’s recommendations. The cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM)/Nut Mix F-12 with 10% foetal
calf serum (Invitrogen) containing 0.2 mM L-glutamine (Invitrogen
Corporation) and 250 mg per mL G-418 (Invitrogen), 100 U pen-
icillin, and 100 mg streptomycin per mL (Invitrogen). The cAMP
experiments were performed essentially as described in earlier
(Ringholm et al, 2003). Briefly, the cells were incubated for 2 h with
5 mCi per mL [8-3H]adenine (Amersham Biosciences, Uppsala,
Sweden). The pelleted cells were pre-incubated for 10 min at 371C
before adding to appropriate concentrations of the stimulant (a-
MSH). The extent of conversion of [3H]ATP to [3H]cAMP was de-
termined by Dowex/alumina sequential chromatography [28]. The
conversion to [3H]cAMP was calculated as a percentage of total
eluted [3H]ATP and was normalized to the recovery of [14C]cAMP.
The cAMP assay was performed in duplicates and repeated three
times for each mutant.
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